1061 related articles for article (PubMed ID: 24620745)
1. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Touznik A; Lee JJ; Yokota T
Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
[TBL] [Abstract][Full Text] [Related]
2. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
3. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
4. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
Rodrigues M; Yokota T
Methods Mol Biol; 2018; 1828():31-55. PubMed ID: 30171533
[TBL] [Abstract][Full Text] [Related]
5. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.
van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA
Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788
[TBL] [Abstract][Full Text] [Related]
6. Exon skipping: a first in class strategy for Duchenne muscular dystrophy.
Niks EH; Aartsma-Rus A
Expert Opin Biol Ther; 2017 Feb; 17(2):225-236. PubMed ID: 27936976
[TBL] [Abstract][Full Text] [Related]
7. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
8. Contributions of Japanese patients to development of antisense therapy for DMD.
Matsuo M; Takeshima Y; Nishio H
Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
[TBL] [Abstract][Full Text] [Related]
9. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.
Aartsma-Rus A; van Ommen GJ
RNA; 2007 Oct; 13(10):1609-24. PubMed ID: 17684229
[TBL] [Abstract][Full Text] [Related]
10. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
11. Translational development of splice-modifying antisense oligomers.
Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
[TBL] [Abstract][Full Text] [Related]
12. Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies.
Hwang J; Yokota T
Expert Rev Mol Med; 2019 Oct; 21():e5. PubMed ID: 31576784
[TBL] [Abstract][Full Text] [Related]
13. Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.
Aartsma-Rus A; Houlleberghs H; van Deutekom JC; van Ommen GJ; 't Hoen PA
Oligonucleotides; 2010 Apr; 20(2):69-77. PubMed ID: 20377429
[TBL] [Abstract][Full Text] [Related]
14. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
Relizani K; Goyenvalle A
Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
[TBL] [Abstract][Full Text] [Related]
15. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
Jarmin S; Kymalainen H; Popplewell L; Dickson G
Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
[TBL] [Abstract][Full Text] [Related]
16. The Pharmacokinetics of 2'-
Bosgra S; Sipkens J; de Kimpe S; den Besten C; Datson N; van Deutekom J
Nucleic Acid Ther; 2019 Dec; 29(6):305-322. PubMed ID: 31429628
[TBL] [Abstract][Full Text] [Related]
17. Next steps for the optimization of exon therapy for Duchenne muscular dystrophy.
Filonova G; Aartsma-Rus A
Expert Opin Biol Ther; 2023 Feb; 23(2):133-143. PubMed ID: 36655939
[TBL] [Abstract][Full Text] [Related]
18. Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy.
Sheikh O; Yokota T
BioDrugs; 2021 Jul; 35(4):389-399. PubMed ID: 34097287
[TBL] [Abstract][Full Text] [Related]
19. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
[TBL] [Abstract][Full Text] [Related]
20. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
